BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Authors » Jim Stommen

Jim Stommen

Articles

ARTICLES

Agile Therapeutics CEO says he's 'all in' on innovation

March 28, 2011
By Jim Stommen

Akron planning for seed fund to lure biomedical companies

March 28, 2011
By Jim Stommen
Turnabout is fair play, reasons the city of Akron, Ohio. Miami successfully lured Akron's native son, LeBron James, to leave the Cleveland Cavaliers and come play for the Florida city's NBA team, the Heat. Now Akron is eyeing a similar ploy, albeit one that will generate far less publicity. (Medical Device Daily)
Read More

Superior capabilities boost hybrid imaging, says report

March 25, 2011
By Jim Stommen
In a new report issued this week, global consulting firm Frost & Sullivan (F&S; Mountain View, California) says that hybrid imaging systems such as PET/CT and SPECT/CT are on the rise and have gained widespread recognition among the medical oncology community. (Medical Device Daily)
Read More

IOM offers clinical standards, effectiveness review guidance

March 24, 2011
By Jim Stommen
Tackling two topics on which there has been much discussion in recent years, the Institute of Medicine (IOM; Washington) has issued recommendations for standards in developing clinical practice guidelines and for systematic review of the comparative effectiveness in medical or surgical procedures. (Medical Device Daily)
Read More

Deals roundup: Quest continues acquisition push with deal to add Celera

March 21, 2011
By Jim Stommen
Continuing its push to grow through acquisitions, global diagnostic testing leader Quest Diagnostics (Madison, New Jersey) said Friday that it would add Celera (Alameda, California), a pioneering genetic diagnostics firm, in a merger deal valued at just over $670 million. (Medical Device Daily)
Read More

ASU researchers eye the use of tears for checking glucose

March 18, 2011
By Jim Stommen

EndoLumina eyes wireless sensing of upper GI bleeding

March 17, 2011
By Jim Stommen

Start-up firm mc10 aiming at combined mapping, ablation

March 15, 2011
By Jim Stommen
A Cambridge, Massachusetts-based start-up company, mc10, is focused on doing more with less, developing "smart" balloons that can eliminate one of the several catheters currently used in cardiac mapping and ablation procedures. (Medical Device Daily)
Read More

Hospital execs expect reform moves to spur their spending

Feb. 21, 2011
By Jim Stommen
The good news in L.E.K. Consulting's newly issued report on the spending plans of U.S. hospitals is that spending on medical equipment, spurred by healthcare reform, is expected to increase substantially. (Medical Device Daily)
Read More

Chris Rivera: President of Washington state life sciences association sees local gains from having a global health perspective

Feb. 1, 2011
By Jim Stommen
View All Articles by Jim Stommen

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing